Navigation Links
Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
Date:6/2/2009

. This study was conducted in more than 100 clinical sites throughout North America. The objective of the study was to show that a 10-day course of fidaxomicin was at least as efficacious (non-inferior) and safe as a 10-day course of Vancocin (vancomycin hydrochloride capsules, USP) for the treatment of CDI.

The primary endpoint of the study was clinical cure defined as patients requiring no further CDI therapy two days after completion of study medication, as determined by the investigator. The secondary endpoint evaluated CDI recurrence up to four weeks post therapy with recurrence defined as the return of diarrhea associated with CDI confirmed by a positive toxin test. Global cure was defined as patients who were cured and did not have a recurrence.

About Clostridium Difficile Infection

CDI has become a growing problem in hospitals, long-term care facilities and in the community. It is a serious illness caused by infection of the inner lining of the colon by C. difficile bacteria, which produce toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death. CDI typically develops from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, allowing C. difficile bacteria to flourish.

Current therapeutic options for CDI include metronidazole and oral vancomycin. However, approximately 20% to 30% of CDI patients who initially respond to these treatments experience a clinical recurrence following cessation of antibiotic administration.

Primary risk factors for CDI include broad-spectrum antibiotic use, advanced age (over 65), emerging hyper-virulent strains (BI /NAP1/027, 078, 001) of C. difficile, and previous exposure to CDI that lead to recurrence. Higher incidence, increased treatment failures, and recurrence with standard therapies have resulted in greater awarene
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Wednesday of last week RENU 28, the world's first and ... for purchase in Australia and New Zealand, and the response ... is, if you think about the definition of aging, it's ... within your body. If you think about the definition of ... What RENU 28 does is it works with these tiny ...
(Date:8/20/2014)... Fla. , Aug. 20, 2014 ... will host a conference call to provide an ... 2014Time:4:30 p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. ... 9126599 Live web cast: www.neurotropebioscience.com , under "Investor ... hours after completion through September 2, 2014 at ...
(Date:8/20/2014)... August 20, 2014 Not long ago, ... studies should be performed late in the development cycle ... But current regulatory trends suggest that, like many things ... rise. In recent years, multiple drug sponsors have been ... address specific questions during phase I/II. It’s not only ...
(Date:8/19/2014)... 20, 2014 One of the ... is an inadequate vascular supply. Nutrient and gas ... tissues is critical for successful regeneration and integration ... mitigate deficiencies in vascularization and promote angiogenesis in ... optimizing scaffold design and architecture, and enhancing scaffolds ...
Breaking Biology Technology:RENU 28 Skin Care Now Available in Australia and New Zealand 2Neurotrope To Host Conference Call 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2
... N.J., Oct. 4 In conjunction with,its third quarter 2007 ... 24), Covance Inc. (NYSE: CVD ) is pleased to ... will be broadcast,live over the Internet on Thursday, October 25 ... Quarter 2007 Earnings Webcast and Slide Presentation When: ...
... Inc.,(NYSE: SMA ), an independent provider of ... medical markets, announced today that the Audit,Committee of ... review of,apparent irregularities with respect to the Company,s ... unit. The review follows a,report by management earlier ...
... today announced that Solomon Steiner, Chairman and CEO of Biodel,will ... San,Francisco, CA on October 11th at 11:00 AM PT. ... webcast of the,presentation in the investor relations section of Biodel,s ... be available for,14 days. About Biodel Inc. Biodel ...
Cached Biology Technology:Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement 2Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement 3Biodel Inc. to Present at BIO InvestorForum 2007 Conference on October 11, 2007 2
(Date:8/21/2014)... smog-producing toxins in past decade, GTA still violates ... that while the Greater Toronto Area (GTA) has ... to smog, the city continues to violate the ... can cause or aggravate health problems such as ... a set of complex photochemical reactions involving volatile ...
(Date:8/21/2014)... 2014 Nxt-ID, Inc. (OTCQB: NXTD), a biometric ... announced today that its shares of common stock and ... in its proposed underwritten public offering of common stock ... Nasdaq Capital Market, subject to closing of its proposed ... and will trade under the symbol "NXTD" and "NXTDW," ...
(Date:8/21/2014)... are the ultimate source of all organic matter that ... algae, too, to suck up climate-warming carbon dioxide from ... the ocean. Now, by using a combination of satellite ... viruses infecting those algae are driving the life-and-death dynamics ... essentially the same, and this has important implications for ...
Breaking Biology News(10 mins):Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3Viruses take down massive algal blooms, with big implications for climate 2
... Boston, MA - Tiny particles only billionths of a meter ... human haircould offer big hope in a small package to the ... everything from jewelry to coins and cell phones, say scientists at ... issue of Nature Nanotechnology, the team will report a ...
... the largest study of its kind, researchers from a consortium ... linked to late-onset Alzheimer,s disease. Each of these genes adds ... the disease, and together they offer a portal into the ... to determine who is at risk of developing the disease, ...
... Medicine researchers are part of a consortium that has identified ... a person developing Alzheimer,s disease later in life. The ... The consortium also contributed to the identification of a ... United States and Europe. "Mount Sinai has unique resources ...
Cached Biology News:Nanoparticles offer hope for common skin allergy 2Nanoparticles offer hope for common skin allergy 3Alzheimer’s disease consortium identifies four new genes for Alzheimer’s disease risk 2Alzheimer’s disease consortium identifies four new genes for Alzheimer’s disease risk 34 new genes identified for Alzheimer's disease risk 2
Bovine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11:...
...
... deuterium atoms at the 9, 10, 12, and ... an internal standard for the quantification of 13(S)-HODE ... by incubation of linoleic acid with plant and ... the adhesion of tumor cells to the endothelium ...
...
Biology Products: